Taken together, our hypothesis that Ripply3 overdosage contributes to midfacial shortening in Down syndrome through the downregulation of Tbx1 is supported by gene expression analyses in the developing branchial arches of both mouse and rat DS models, as well as by genetic dosage rescue experiments in the Dp(16)1Yey model. Here, RIPPLY3 is linked to Down syndrome.